News & Events
Here you will find the most up to date information related to Virtual News Rheum.
May 20 2019 - 10:00am
WALTHAM, Mass., May 20, 2019 PRNewswire -- Corrona, LLC is pleased to announce a key milestone for the Corrona® Multiple Sclerosis (MS) Registry, a real-world US-based registry developed as a collaborative effort with the National MS Society. The collaborative registry model now includes Genentech, a member of the Roche Group, as the first pharmaceutical company to support and participate in the registry. The Corrona MS Registry was created in 2017 to study the real-world effectiveness and safety of approved therapies for MS. Corrona's sixth registry, the MS Registry collects high-quality...
Dec 11 2017 - 8:00am
Portland, Ore. (December 11, 2017)— The Corrona® Psoriasis Registry, a joint collaboration between the National Psoriasis Foundation (NPF) and Corrona, LLC, the leading sponsor of registries in autoimmune and immune-mediated diseases, announces it has expanded into Canada and has enrolled its first Canadian psoriasis patient. With this expansion, the new Canadian sites and patients join a U.S. network of more than 230 participating dermatology health care providers and 3,700 patients already participating in the Corrona® Psoriasis Registry. “We very much look forward to working with Canadian...
Corrona and the National Multiple Sclerosis Society announce intent to collaborate on a multiple sclerosis registry to study the comparative effectiveness and safety of approved therapies
Oct 20 2017 - 7:15am
WALTHAM, Mass., Oct. 20, 2017 /PRNewswire/ -- Corrona, LLC and the National Multiple Sclerosis Society have announced their intent to collaborate on the launch of the Corrona Multiple Sclerosis (MS) Registry to study the comparative safety and effectiveness of approved MS therapies. The first patient has been enrolled, with initial recruitment goals to register approximately 5,000 people with MS. This national, observational registry will collect and analyze longitudinal outcomes associated with multiple sclerosis therapies. The MS registry is Corrona's sixth patient registry, adding to...
Sep 14 2017 - 8:00am
According to results of an observational analysis, the efficacy of adalimumab is sustained in rheumatoid arthritis (RA) patients who continued therapy for 10 years. Biologic-naïve RA patients who had enrolled in the Corrona RA registry after initiating adalimumab during follow-up were included in the study. Over 10 years of data regarding the persistency of adalimumab as well as the reasons for medication discontinuation were evaluated. The study authors stated, “Among patients who persisted on adalimumab over the years, clinical [e.g., clinical disease activity index scores (CDAI), physician...
Aug 14 2017 - 10:30am
by Ed Susman, Contributing Writer, MedPage Today ORLANDO -- Rheumatoid arthritis (RA) patients who received tocilizumab (Actemra) with methotrexate achieved low disease activity and could discontinue methotrexate while maintaining disease control, researchers said here. In a study designed to evaluate whether tocilizumab monotherapy was non-inferior to the combination, patients who achieved a DAS28-ESR (Disease Activity Score) of 3.2 or lower at week 24 were eligible for the trial to determine if they could safely discontinue methotrexate, according to Joel Kremer, MD, of Albany Medical...
Jul 20 2017 - 8:00am
Healio Rheumatology, July 2017 With each passing year, big data has taken on a larger role in medicine and more specifically, in rheumatology. “Here is the thing about big data, it is not new. Health plans have been using big data for a long time,” Catherine MacLean, MD, PHD, from Hospital for Special Surgery, told Healio Rheumatology. “What is new in big data is that these sources of data are now becoming more available.” To better understand big data, Healio Rheumatology spoke with leaders of the Corrona, ArthritisPower, BRASS, ImmPort and RISE registries and discussed what these registries...
Jun 16 2017 - 8:00am
Real-world evidence (RWE) is increasingly important to clinicians, regulators and payers Regional and local registries are a valuable source of RWE The large Corrona RA US registry has revealed information revenant to clinical practice (e.g. non-adhearance, effectiveness and safety of biologics, orals and DMARDs, quality of life) RWE complements data from clinical trials Several challenges remain in the treatment of RA Many patients do not take MTX as prescribed due to side effects or inadequate response Reimbursement barriers in some countries may reduce patients’ chances of achieving...
IBD News Today - Corrona Enrolls First Patient in Novel IBD Registry to Study Crohn’s Disease, Ulcerative Colitis
Jun 13 2017 - 8:00am
Corrona, a provider of U.S. disease registries, has enrolled the first patient in its novel inflammatory bowel disease (IBD) registry, launched in May 2017. This is the first national registry to collect data from patients with ulcerative colitis, Crohn’s disease and other IBDs. Corrona joined the Crohn’s and Colitis Center at Brigham and Women’s Hospital of Harvard Medical School and Pfizer to provide expertise, tools and resources that fit with the drug discovery process. Read more... https://ibdnewstoday.com/2017/06/13/corrona-announces-first-patient-enro...
Jun 1 2017 - 1:15pm
SOUTHBOROUGH, Mass., June 1, 2017 /PRNewswire — Corrona, a nationwide provider of disease registries, announced that the first patient has been enrolled in its groundbreaking Inflammatory Bowel Disease (IBD) Registry. No national registry presently collects data from patients with inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Corrona established strategic partnerships with industry leaders supporting IBD disease therapies. Our partners provide expertise, tools and resources that compliment the research discovery process."I am immensely gratified and excited...
Jan 3 2017 - 8:00am
by Nancy Walsh Senior Staff Writer, MedPage Today: Dimitrios A. Pappas, MD, of Columbia University and the Corrona registry, talked to MedPage Today about a recent study evaluating whether or not the use of glucocorticoids influenced the time to initiating biologic therapy among patients with rheumatoid arthritis. This was published online in a special supplement to Arthritis & Rheumatology. For a description of this CME program, please click here. A copy of the presentation poster can be downloaded here.Following is a transcript of his remarks: The rationale for investigating what is...